シンクロン原発性早期非小細胞肺がん: 管理の傾向と生存率の改善に関連する要因
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。シンクロン・プライマリー・エールステージI非小細胞肺がん (SPELC) のアウトカムは,治療によって異なります. 外科手術による生存率は最も高く,SBRTによる手術と外科手術による生存率はほぼ同じです.
科学分野
- 胸部腫瘍学
- 放射線腫瘍学
- 手術腫瘍学
背景
- 治癒の意図で治療された同期原発性早期I型非小細胞肺がん (SPELC) のアウトカムについては,十分に理解されていません.
- マルチモダリティの治療法は一般的ですが,比較効果は不明です.
研究 の 目的
- SPELC患者の治療利用と生存結果を評価する.
- 治療方法に基づいて全生存率 (OS) と無疾患生存率 (DFS) を比較する.
主な方法
- 2006年から2024年までのステージIのSPELCを患った835人の退役軍人の遡及分析.
- 治療グループには,ステレオタキシ体放射線療法-SBRT,SBRT手術,および手術-手術が含まれていました.
- コックスの比例リスクモデルは,OSとDFSに関連する要因を評価した.
主要な成果
- ステレオタクティック・ボディ・放射線療法 (SBRT) は,併発症の高齢患者でより多く使用されました.
- 5年間のOSは51. 7% (SBRT-SBRT),72% (SBRT-手術),66. 7% (手術-手術) である.
- 5年間のDFS: 42.7% (SBRT-SBRT), 42.6% (SBRT-外科), 57.26% (外科-外科) SBRT-SBRTとSBRT-Surgeryは劣ったDFSでした.
結論
- ステージIのSPELCを患った退役軍人の治療方法が結果に大きく影響します.
- 手術-手術は優れたDFSを提供し,OSは手術-手術とSBRT-手術のグループ間で類似していました.
- 患者の選択と治療戦略は,SPELCの結果を最適化するために不可欠です.
関連する概念動画
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...